Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 110 East 59th Street NEW YORK NY 10022 |
Tel: | N/A |
Website: | https://www.royaltypharma.com |
IR: | See website |
Key People | ||
Pablo Legorreta Chairman of the Board, Chief Executive Officer | Christopher D. Hite Vice Chairman, Executive Vice President | Terrance Coyne Chief Financial Officer, Executive Vice President |
George Lloyd Executive Vice President - Investments and Chief Legal Officer | Marshall Urist Executive Vice President - Research and Investments | Eric Schneider Senior Vice President, Chief Technology Officer |
Business Overview |
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Novartis' Promacta, Pfizer's Nurtec ODT and Gilead's Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others. |
Financial Overview |
For the three months ended 31 March 2024, Royalty Pharma plc revenues decreased 17% to $568M. Net income decreased 99% to $4.8M. Revenues reflect Income from financial royalty assets decrease of 19% to $541.5M. Net income also reflects Provision for changes in expected cash f increase from $118.8M to $583.6M (expense), Equity in loss of non-consolidated affil decrease from $34.6M (income) to $14.1M (expense). |
Employees: | 89 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $21,389M as of Mar 31, 2024 |
Annual revenue (TTM): | $2,239M as of Mar 31, 2024 |
EBITDA (TTM): | $939.40M as of Mar 31, 2024 |
Net annual income (TTM): | $798.86M as of Mar 31, 2024 |
Free cash flow (TTM): | $655.20M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | $4,607M as of Mar 31, 2024 |
Shares outstanding: | 597,487,030 as of Mar 31, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |